• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

银屑病关节炎:是否到了达标治疗或针对治疗的时机?

Psoriatic arthritis: is it time to treat-to-target or target to treat?

机构信息

Dipartimento di Medicina e di Scienze della Salute "Vincenzo Tiberio", Università degli studi del Molise, Via Giovanni Paolo II, C/da Tappino, 86100, Campobasso, Italy.

出版信息

Clin Rheumatol. 2017 Dec;36(12):2633-2635. doi: 10.1007/s10067-017-3885-1. Epub 2017 Oct 24.

DOI:10.1007/s10067-017-3885-1
PMID:29067586
Abstract

Treat-to-target recommendations provide physicians a useful strategy to reduce the probability of disease progression and in general to manage PsA patients. However, it could be difficult to apply in real life, since PsA is a very heterogeneous disease with different manifestations to be treated. In fact, depending on the patient's expectation, some aspects of the disease could be prominent or not, beyond the mere achievement of the target of remission or low-disease activity. In this context, the concept of a "target to treat" strategy should be taken in to account.

摘要

达标治疗建议为医生提供了一种有用的策略,可以降低疾病进展的概率,并通常可以管理银屑病关节炎患者。然而,在实际生活中应用可能会有困难,因为银屑病关节炎是一种表现各异的非常异质的疾病,需要进行不同的治疗。事实上,除了实现缓解或低疾病活动度的目标外,根据患者的期望,疾病的某些方面可能会更加突出或不那么突出。在这种情况下,应该考虑采用“达标治疗”策略的概念。

相似文献

1
Psoriatic arthritis: is it time to treat-to-target or target to treat?银屑病关节炎:是否到了达标治疗或针对治疗的时机?
Clin Rheumatol. 2017 Dec;36(12):2633-2635. doi: 10.1007/s10067-017-3885-1. Epub 2017 Oct 24.
2
Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.银屑病关节炎当前治疗方法的改进需求:门诊患者群体研究
J Rheumatol. 2017 Apr;44(4):431-436. doi: 10.3899/jrheum.160973. Epub 2017 Feb 1.
3
Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study.类风湿关节炎和银屑病关节炎患者压痛关节数和肿胀关节数与患者及评估者整体评估的不相符可能会降低缓解的可能性:来自前瞻性多中心 NOR-DMARD 研究的数据。
Ann Rheum Dis. 2017 Apr;76(4):708-711. doi: 10.1136/annrheumdis-2016-210283. Epub 2016 Oct 4.
4
Implementing Psoriatic Arthritis Disease Activity Score-guided treat-to-target in psoriatic arthritis routine clinical practice: (im)possible?在银屑病关节炎的常规临床实践中实施银屑病关节炎疾病活动评分引导的达标治疗:(不)可行?
Rheumatology (Oxford). 2019 Dec 1;58(12):2330-2331. doi: 10.1093/rheumatology/kez254.
5
Clinical remission in rheumatoid arthritis and psoriatic arthritis.类风湿关节炎和银屑病关节炎的临床缓解。
Clin Exp Rheumatol. 2018 Sep-Oct;36(5):900-910. Epub 2018 Mar 16.
6
What Should Be the Primary Target of "Treat to Target" in Psoriatic Arthritis?银屑病关节炎“达标治疗”的主要目标应该是什么?
J Rheumatol. 2019 Jan;46(1):38-42. doi: 10.3899/jrheum.180267. Epub 2018 Sep 15.
7
Novel Concepts in Psoriatic Arthritis Management: Can We Treat to Target?银屑病关节炎治疗新理念:可否靶向治疗?
Curr Rheumatol Rep. 2018 Sep 18;20(11):71. doi: 10.1007/s11926-018-0781-x.
8
Validation of new potential targets for remission and low disease activity in psoriatic arthritis in patients treated with golimumab.验证新型潜在靶点在接受戈利木单抗治疗的银屑病关节炎患者缓解和低疾病活动度中的作用。
Rheumatology (Oxford). 2019 Mar 1;58(3):522-526. doi: 10.1093/rheumatology/key359.
9
Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study.使用乌司奴单抗治疗的银屑病关节炎患者的最小疾病活动度:一项为期24周的真实世界研究结果
Clin Rheumatol. 2017 Jul;36(7):1589-1593. doi: 10.1007/s10067-017-3700-z. Epub 2017 May 31.
10
Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.接受抗TNF-α药物治疗的银屑病关节炎患者的最小疾病活动度与缓解情况
J Rheumatol. 2016 Feb;43(2):350-5. doi: 10.3899/jrheum.150805. Epub 2015 Dec 15.

引用本文的文献

1
Sequencing of Biologic and Target Synthetic Disease-Modifying Anti-Rheumatic Drugs in Psoriatic Arthritis: Are we Ready to Redefine the Treatment Strategy? A Perspective.银屑病关节炎中生物制剂和靶向合成改善病情抗风湿药的序贯治疗:我们准备好重新定义治疗策略了吗?一种观点。
Rheumatol Ther. 2023 Apr;10(2):301-306. doi: 10.1007/s40744-022-00514-0. Epub 2022 Dec 10.
2
Consensus-based recommendations on the diagnosis, referral and clinical management of patients with psoriatic arthritis.基于共识的银屑病关节炎患者诊断、转诊和临床管理建议。
Rheumatol Int. 2022 Mar;42(3):391-401. doi: 10.1007/s00296-021-05029-5. Epub 2021 Oct 30.
3

本文引用的文献

1
Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.比较针对接受 csDMARD 和 bDMARD 治疗的银屑病关节炎的综合指标:一项纵向队列的横断面分析。
J Rheumatol. 2017 Aug;44(8):1159-1164. doi: 10.3899/jrheum.170112. Epub 2017 Jun 1.
2
Psoriatic Arthritis.银屑病关节炎
N Engl J Med. 2017 Mar 9;376(10):957-970. doi: 10.1056/NEJMra1505557.
3
Defining Low Disease Activity States in Psoriatic Arthritis Using Novel Composite Disease Instruments.
Assessment of the Patient Acceptable Symptom State (PASS) in psoriatic arthritis: association with disease activity and quality of life indices.
评估银屑病关节炎患者可接受的症状状态 (PASS):与疾病活动度和生活质量指标的相关性。
RMD Open. 2020 Mar;6(1). doi: 10.1136/rmdopen-2020-001170.
4
Role of comorbidities in spondyloarthritis including psoriatic arthritis.合并症在包括银屑病关节炎在内的脊柱关节炎中的作用。
Clin Rheumatol. 2019 Jan;38(1):3-10. doi: 10.1007/s10067-018-4332-7. Epub 2018 Oct 18.
使用新型综合疾病工具定义银屑病关节炎的低疾病活动状态。
J Rheumatol. 2016 Sep;43(9):1765-6. doi: 10.3899/jrheum.160386.
4
Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study.皮下注射抗TNF-α可诱导银屑病关节炎患者持续达到最小疾病活动度及缓解:一项回顾性研究。
Postgrad Med. 2016 Sep;128(7):693-6. doi: 10.1080/00325481.2016.1220809. Epub 2016 Aug 16.
5
Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors.肿瘤坏死因子抑制剂治疗中轴型银屑病关节炎的治疗反应、缓解及最小疾病活动度评估
J Rheumatol. 2016 May;43(5):918-23. doi: 10.3899/jrheum.151404. Epub 2016 Mar 15.
6
Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis.超越 TNF 抑制剂:治疗银屑病关节炎的新途径和新兴疗法。
Drugs. 2016 Apr;76(6):663-73. doi: 10.1007/s40265-016-0557-4.
7
Patients with Psoriatic Arthritis Fulfilling the Minimal Disease Activity Criteria Do Not Have Swollen and Tender Joints, but Have Active Skin.符合最小疾病活动标准的银屑病关节炎患者虽无关节肿胀和压痛,但有皮肤病变。
J Rheumatol. 2016 May;43(5):907-10. doi: 10.3899/jrheum.151101. Epub 2016 Mar 1.
8
Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.接受抗TNF-α药物治疗的银屑病关节炎患者的最小疾病活动度与缓解情况
J Rheumatol. 2016 Feb;43(2):350-5. doi: 10.3899/jrheum.150805. Epub 2015 Dec 15.
9
Defining Low Disease Activity States in Psoriatic Arthritis using Novel Composite Disease Instruments.使用新型综合疾病工具定义银屑病关节炎的低疾病活动状态。
J Rheumatol. 2016 Feb;43(2):371-5. doi: 10.3899/jrheum.150826. Epub 2015 Dec 15.
10
An overview of low disease activity and remission in psoriatic arthritis.银屑病关节炎的低疾病活动度和缓解概述
Clin Exp Rheumatol. 2015 Sep-Oct;33(5 Suppl 93):S51-4. Epub 2015 Oct 15.